ClinicalTrials.Veeva

Menu

Intraoperative Infusion of Either Lidocaine or Dexmedetomidine on Regional Cerebral Oxygen Saturation and Postoperative Delirium in Elderly Patients Undergoing Abdominal Surgeries

T

Tanta University

Status

Enrolling

Conditions

Abdominal Surgeries
Dexmedetomidine
Lidocaine
Cerebral Oxygen Saturation
Intraoperative Infusion
Elderly Patients
Postoperative Delirium

Treatments

Drug: Lidocaine
Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT07108764
36265MD399/4/25

Details and patient eligibility

About

This study aims to compare the effect of intraoperative infusion of either lidocaine or dexmedetomidine on the incidence of postoperative delirium (POD) in elderly patients undergoing major surgeries. It also aims to evaluate the impact of both medications on intraoperative regional cerebral oxygen saturation (rSO₂).

Full description

Postoperative delirium (POD) is a significant complication in elderly patients undergoing major surgery, with an incidence ranging from 10% to 50%, depending on patient and surgical factors.

Regional cerebral oxygen saturation (rSO₂), measured using near-infrared spectroscopy (NIRS), provides a real-time, non-invasive marker of cerebral perfusion. Previous studies have demonstrated that intraoperative declines in rSO₂ are associated with an increased risk of POD.

Lidocaine, an amide local anesthetic, has been shown to reduce neuroinflammation, improve microcirculation, and exert neuroprotective effects. It has been associated with low postoperative pain, reduced opioid consumption, and improved cognitive outcomes.

Dexmedetomidine, an α2-adrenergic agonist, is known for its sedative, analgesic, and sympatholytic effects. It has been shown to enhance cerebral perfusion, improve rSO₂, and reduce POD incidence.

Enrollment

100 estimated patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 65years old.
  • Both sexes.
  • Physical status classification of II - III according to the American Society of Anesthesiologists (ASA).
  • Undergo elective non-cardiac surgeries.

Exclusion criteria

  • History of mental illness, neurological illness, or scoring less than 8 using the abbreviated mental test (AMT) before operation.
  • Severe hearing or visual impairment that may interfere with communication.
  • Severe renal or hepatic dysfunction.
  • Patients on central nervous system (CNS) medications (antipsychotics, anticonvulsants, antiparkinsonian, antidepressants).
  • Contraindications to lidocaine or dexmedetomidine [e.g., allergy, severe bradycardia, atrioventricular (AV) block].

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

100 participants in 2 patient groups

Lidocaine group
Experimental group
Description:
Patients will receive an IV bolus (50 ml) of lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. This will be followed by intraoperative lidocaine infusion in a dose of 1.5mg /kg/hr till the end of surgery.
Treatment:
Drug: Lidocaine
Dexmedetomidine group
Experimental group
Description:
Patients will receive an IV bolus (50 ml) of dexmedetomidine in dose 0.5 μg/kg over 10 min before induction of anesthesia. This will be followed by intraoperative dexmedetomidine infusion in a dose of 0.3 μg/kg/hr till the end of surgery.
Treatment:
Drug: Dexmedetomidine

Trial contacts and locations

1

Loading...

Central trial contact

Dina H Alhassanin, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems